Enliven Therapeutics Inc
ELVN
Company Profile
Business description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Contact
6200 Lookout Road
BoulderCO80301
USAT: +1 720 647-8519
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
65
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,841.37 | 19.37 | 0.25% |
| DAX 40 | 24,377.35 | 6.42 | 0.03% |
| Dow JONES (US) | 44,484.49 | 229.71 | 0.52% |
| FTSE 100 | 8,977.21 | 4.57 | 0.05% |
| HKSE | 24,825.66 | 326.71 | 1.33% |
| NASDAQ | 20,885.65 | 155.16 | 0.75% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,297.36 | 33.66 | 0.54% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |